Economic Evaluation of an Asthma Therapy: Effect of Salmeterol on Loss of Labor Productivity in Japan  by Miyagawa, Takehiko & Nishimura, Shuzo
Economic Evaluation of an Asthma
Therapy: Effect of Salmeterol on Loss
of Labor Productivity in Japan
Takehiko Miyagawa1 and Shuzo Nishimura2
ABSTRACT
Background: Asthma can have a negative impact on the productivity of paid and unpaid individuals. In this
study, we aimed to investigate the impact of salmeterol, which, in recent years, has become available for the
treatment of asthma in Japan, on the productivity of patients with asthma.
Methods: Relevant data were extracted from the medical records of 54 patients aged15 years with moder-
ate or severe asthma. Loss of productivity was estimated via the human capital approach in the year before
and the year after introduction of salmeterol.
Results: Lost productivity was significantly reduced (p< 0.001) after salmeterol’s introduction compared to the
period before its introduction in both paid labors and unpaid ones. Reduced loss of productivity avoided loss of
approximately 800,000 yen in the paid ones and 61.3 days in unpaid ones. It was estimated that loss of about
105.4 billion yen in the paid group and 64.5 billion yen in the unpaid group could be avoided if this result was
expanded to the wider society. In paid labors, productivity loss was avoided when symptoms were absent dur-
ing the day, irrespective of the presence or absence of symptoms during the night, whereas, in the unpaid
group, the loss was avoided when symptoms were absent during the day or night.
Conclusions: It was considered that improvement of clinical symptoms, which occurred in association with
the introduction of salmeterol, resulted in avoidance of losses in productivity that had previously occurred in pa-
tients with asthma.
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INTRODUCTION
Salmeterol xinafoate (SereventⓇ ) is a new inhala-
tional phenylethanolamine β2 adrenoceptor-
stimulating bronchodilator. The drug is highly selec-
tive for β2 adrenoceptors, and exhibits a sustained ef-
fect, although the onset of its effect is slow. There-
fore , in contrast to fast , short-acting β2 stimulants ,
which are used for acute relief of asthmatic symp-
toms, salmeterol can be used daily in order to prevent
the onset of asthma attacks. Several randomized con-
trolled trials ( RCTs ) published in Japan , 1,2 have
shown that salmeterol is more effective than other β2
stimulants in the treatment of bronchial asthma.
Bronchial asthma is a chronic inflammatory dis-
ease accompanied by airway occlusion. In general ,
the treatment of bronchial asthma involves admini-
stration of steroids and antiallergic agents in order to
suppress airway inflammation, and administration of
xanthine derivatives and β2 stimulants in order to re-
lieve airway occlusion. In Japan, multi-drug therapy,
which involves combinations of such drugs , is
adopted depending on the patient’s condition．
Salmeterol , which was introduced more than 10
years ago in foreign countries, was marketed in June
2002 in Japan and has become one of the popular
choices for asthma treatment. There have, however,
been concerns that the addition of a new inhalational
drug to treatment regimens could be burdensome for
patients who are taking a number of other oral and in-
halational drugs. However, we previously conducted
a patient questionnaire survey,3 which revealed that
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Table 1 Parameters used in the analysis
SourceParameterItem
Basic Survey of Wage Structure 
(2002 version)
14,000Producer
Daily wage (men) 19,300Manager/engineer
19,900Part-time worker
8,900Producer
Daily wage (women) 11,100Manager/engineer
11,700Part-time worker
Handbook of Labour Statistics 
(2002 version)
66,890,000Total labor population
Survey on patients (2002 version)
1,069,000Estimated total number of patients
1,600Estimated total number of patients (inpatients)
141,200Estimated number of patients/month†
74,600Estimated number of patients/month‡
† Total number of outpatients (children and adults)
‡ Total number of adult outpatients
an additional inhalational drug could be administered
without adding an emotional burden in patients with
asthma, provided that sound guidance for the inhala-
tional therapy is given.
International guidelines for the treatment and man-
agement of asthma, provided by The National Heart,
Lung, and Blood Institute and the World Health Or-
ganization (Global Initiative for Asthma ; GINA :
2002 revised version : GINA2002),4 recommend com-
bined therapy with inhaled corticosteroids (ICS) and
long-acting β2-agonists (LABAs) for the treatment of
moderate (Step 3) to severe (Step 4) chronic asthma.
In Japan, the role of LABAs has been elucidated in
the revised version of the guidelines relating to the
treatment and management of asthma issued by the
Japanese Society of Allergology in 2003. 5 These
guidelines state that the combination of ICS and LA-
BAs is“useful for poorly controlled asthma”on the
basis of evidence-based medicine for medical tech-
niques given by the British Medical Association．
International studies have found that combined
therapy with ICS and LABAs can improve clinical,6,7
patient-reported8 and economic 9 outcomes in com-
parison with a combination of ICS and oral drugs.
Such reports have caused us to question the effective-
ness of oral multi-drug combination therapy, as used
in Japan. Thus, we considered that it was necessary
to examine the effects of combination therapy with
ICS and LABAs, issued in accordance with the GINA
Guidelines, in Japan, not only with regard to clinical
outcomes but also regarding the economic impact of
asthma, including direct medical costs and indirect
costs, such as the impact of the disease on patient
productivity．
The current investigational study was aimed at ret-
rospectively quantifying the benefits of asthma treat-
ment using salmeterol combined with ICS, adminis-
tered in compliance with the GINA Guidelines. The
study was conducted from an economic point of view,
focusing on patient productivity.
METHODS
STUDY DESIGN
This study is a longitudinal retrospective study de-
signed to comparatively examine the impact of
asthma on economic measures during the year be-
fore and the year after the introduction of salmeterol.
The technique of cost analysis was used to examine
the loss in productivity from the perspective of the pa-
tients participating in the study . The duration of
analysis was set for one year in order to compare the
year before the introduction of salmeterol to the year
after its introduction. Discounting10 calculations were
not employed.
SELCTION OF SUBJECTS
Using a simple sampling method, study participants
were randomly selected from a population of 1080 pa-
tients who had consulted our hospital in 2002. To be
eligible for inclusion , patients were required  15
years of age, having a diagnosis of step3 to 4 bron-
chial asthma and to be receiving combination therapy
consistings of ICS plus leukotriene modifiers, inhaled
short-acting β2 stimulants, andor sustained theophyl-
line, etc. In addition, patients were required to have
no serious comorbidities and must have been receiv-
ing stable doses of medication for asthma, other than
ICS, prior to receiving salmeterol. Approximately 270
patients met the criteria for inclusion. Patient data re-
lating to demographics, clinical findings, medical fee
points, daily symptoms, number of unscheduled visits
requiring a drip infusion of either corticosteroids or
aminophylline , were collected retrospectively from
medical records and asthma diaries from those pa-
tients who agreed to participate in the study. Find-
ings were entered into a database using MicrosoftⓇ
Excel 2000Ⓡ (Microsoft Corporation, Redmond, WA,
USA) . No information regarding emergency room
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Calculations for the estimation of labor populations with asthma are as folows:
Total labor population/Total population × 100 = 61.2% (the ratio of labor population to the total population) ―――――――― [1]
Estimated total number of patients - Estimated total number of inpatients = Total number of outpatients estimated  ―――― [2]
Estimated number of adult outpatients per month/Estimated number of total outpatients per month × 100 = 52.8% (the ratio oc-
cupied by the number of adult outpatients to the total number of outpatients/month estimated) ――――――――――――― [3]
[2](Total number of outpatients estimated) × [3](52.8%)
= Total number of adult outpatients estimated ―――――――――――――――――――――――――――――――――― [4]
[4](Total number of adult outpatients estimated) × [1](61.2%)
= total number of adult outpatients estimated (only paid labors) ―――――――――――――――――――――――――― [5]
[4](Total number of adult outpatients estimated - [5]
(total number of adult outpatients estimated : only paid ones)
= total number of adult outpatients estimated (only unpaid ones) ――――――――――――――――――――――――― [6]
Oficial statistical data used in the calculations above are shown in Table 1.
visits, hospitalizations, and consultations with other
hospitals was collected as no such records were avail-
able．
OUTCOMES
The primary economic outcome in this analysis was
defined as loss of productivity in asthma patients .
Loss of productivity in each subject was estimated us-
ing the human capital approach (involves the number
of days affected by loss).11 Subjects were classified
into salaried workers (paid labors : further classified
into full-time workers and part-time workers ) and
non-recipient workers, such as full-time housewives.
The mean income value for paid labors was calcu-
lated according to gender and occupation based on
the wages of full- and part-time employees of 3 major
industries (manufacturing, construction and mining)
published in the Ministry of Health, Labour and Wel-
fare Labour Statistics (2002)(Table 1).12 Loss of pro-
ductivity (expressed in yen for paid labors and days
for unpaid ones) was calculated assuming that se-
vere, moderate and mild attacks, stridor and absence
of attacks in the asthma diary corresponded to 100%,
75%, 50%, 25% and 0% loss of productivity , respec-
tively．
Clinical outcome measures consisted of symptom-
free days (SFDs) and symptom-free nights (SFNs).
SFDs were defined as the number of days during
which asthma symptoms were completely absent for
24 hours according to the asthma diary. SFNs were
defined as the number of nights during which asthma
symptoms were completely absent according to the
asthma diary．
ESTIMATION OF THE IMPACT ON JAPAN SOCI-
ETY
The impact of asthma on society in general was esti-
mated as follows by utilizing official statistics
data, 13,14 such as the total labor population and total
population of patients with asthma (Table 1), and ap-
plying calculated losses in productivity in the paid
and unpaid groups to the estimated relevant labor
populations.
ETHICAL CONSIDERATION
Prior to starting the investigation, the study was ex-
plained to subjects. Written, informed consent to use
personal information was obtained from the subjects
in compliance with Japanese ethical guidelines15 for
epidemiological studies published by the Ministry of
Education, Culture, Sports, Science and Technology
and Ministry of Health, Labour and Welfare.
STATISTICAL ANALYSIS
The effect of asthma on productivity before and after
the introduction of salmeterol was compared in each
of the paid and unpaid groups using the Wilcoxon’s
signed rank test or paired t -test. Before performing
paired t -tests, equal variation was examined by the F
test to judge whether the data were distributed
equally before and after the introduction of sal-
meterol. The risk difference (RD) in the mean values
before and after the introduction of salmeterol was
calculated and its 95% confidence interval (CI) was
determined. The Pearson’s product-moment correla-
tion coefficient was used in order to examine the rela-
tionship between the loss of productivity and clinical
outcomes (SFDs and SFNs). Finally a one-way sensi-
tivity analysis, by excluding the data for step 2 group,
was undertaken in order to confirm influence of ex-
clusion of the patient group．
Differences were considered statistically significant
at a significance level of 5%. Analysis software was
mainly SPSSⓇ Base 11.0JⓇ (SPSS Japan Inc., Tokyo,
Japan) and MicrosoftⓇ Excel 2000Ⓡ.
RESULTS
PATIENTS’ BACKGROUND
Of the 54 eligible patients in this study, 33 were paid
labors and 21 were unpaid ones. In the paid group, 18
subjects (54.5%) were females with a mean age of
55.6 years (Table 2). Twenty-seven patients were full-
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Fig. 1 Productivity loss in the paid patient group (n = 33) 
before and after introduction of salmeterol to the Japanese 
market. ＊＊＊ p < 0.001; risk diference = -782.8 (95% CI: 
-999.3～-566.3)
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＊＊＊Table 2 Baseline characteristics of the subjects
Unpaid labors
(%)
Paid labors
(%)
Item
2133Total number of patients
5/1615/18Sex (men/women)
67.4 ± 13.655.6 ± 11.6Mean age (SD)
 2 (9.5) 4 (12.1)Step 2
Severity 18 (85.7)24 (72.7)Step 3
 1 (4.8) 5 (15.2)Step 4
12 (57.1)23 (69.7)Unscheduled visits
experienced
N/A27 (81.8)Ful-time
Occupation
N/A 6 (18.2)Part-time
SD: standard deviation, N/A: not available
Paid labors: Patients who have regular or iregular incomes
Unpaid labors: Patients without regular or iregular income
time workers while the remaining 6 were part-time
workers. In the unpaid group, 16 subjects (76.2%)
were females with a mean age of 67.4 years (Table 2).
Disease severity for all eligible patients was reas-
sessed after enrollment using a matrix table of fre-
quency and clinical symptoms. Of the 33 patients in
paid labor, 4 (12.1%) had step 2 disease, 24 (72.7%)
had step 3 disease, and 5 (15.2%) had step 4 disease
(Table 2).Of the 21 patients in unpaid labor, 2 (9.5%)
had step 2 disease, 18 (85.7%) had step 3 disease, and
1 (4.8%) had step 4 disease (Table 2). Prior to the use
of salmeterol, 23 (69.7%) patients in paid labor and 12
(57.1%) patients in unpaid labor had an unscheduled
visit requiring a drip infusion of either corticosteroids
or aminophylline (Table 2).
CLINICAL FINDINGS
Following the introduction of salmeterol there was a
statistically significant improvement in the number of
SFDs in both patient groups : 120.7 days per year in
paid patients ( 95% confidence interval [CI] 83.2 ―
158.2 ; p < 0.001) and 159.2 days per year in unpaid
patients (95% CI 99.4―218.9 ; p < 0.001)(Table 3).
There was also a statistically significant improvement
in SFNs in both patient groups : 42.5 nights per year
in paid patients (95% CI -17.5―102.3 ; p < 0.001) and
84.3 nights per year in unpaid patients (95% CI 24.2―
144.4 ; p < 0.001)(Table 3). Although the number of
unscheduled visits was significantly reduced by an av-
erage of 6.2 days (95% CI 2.9―9.5 ; p < 0.001) in paid
patients, they were not significantly reduced in un-
paid ones (mean reduction of 3.8 days [95% CI -10.9―
3.3])(Table 3).
IMPACT OF ASTHMA ON PRODUCTIVITY BE-
FORE AND AFTER THE INTRODUCTION OF
SALMETEROL
In the paid group, the null hypothesis that distribu-
tion of data before and after the introduction of sal-
meterol would show equal variation was rejected at a
significance level of 5%. The Wilcoxon’s signed rank
test , which is a non-parametric test , was therefore
used to compare data before and after the introduc-
tion of salmeterol. The result showed a statistically
significant reduction (p < 0.001) in lost productivity af-
ter the introduction of salmeterol compared to the pe-
riod before its introduction (Fig. 1). Estimation of RD
(the difference before and after the introduction) re-
vealed a saving of about 800,000 yen ( 95% CI :
569,300―999,300 yen, median : 625,950 yen) from re-
duced loss of productivity after the introduction of
salmeterol (Fig. 1).
In the unpaid group, the null hypothesis that lost
productivity would be similar before and after the in-
troduction of salmeterol was also rejected (p = 0.041).
The Wilcoxon’s signed rank test revealed that there
was a statistically significant (p < 0.001) reduction in
productivity loss after the introduction of salmeterol
compared to the year before it was introduced
(Fig. 2).Estimation of RD revealed a reduction of
about 61.3 days (95% CI : 41.2―81.3, median : 51.0
days) after the introduction of salmeterol compared
to lost productive days before the drug was intro-
duced to patients (Fig. 2).
CORRELATION BETWEEN LOSS OF PRODUC-
TIVITY AND CLINICAL OUTCOMES
When the relationship between productivity loss and
clinical outcomes was examined, a moderately sized
negative correlation (r = −0.689, p < 0.001) was de-
tected between SFDs and the statistically significant
reduction in lost productivity after the introduction of
salmeterol in the paid group (Table 4). However ,
there was only a small negative correlation between
SFNs and the change in loss of productivity. In the
unpaid group, moderately sized, significant negative
correlations were detected between symptom-free
status, irrespective of whether it was day or night ,
and the statistically significant reduction in lost pro-
ductivity after the introduction of salmeterol (Ta-
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Fig. 2 Productivity loss in the unpaid patient group (n = 21) 
before and after introduction of salmeterol to the Japanese 
market. ＊＊＊p < 0.001; risk diference = -61.3 (95% CI: -81.3
～-41.2)
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IMPACT OF ASTHMA ON SOCIETY IN GENERAL
BEFORE AND AFTER THE INTRODUCTION OF
SALMETEROL
Overall, the asthmatic labor population was estimated
to contain 341,679 paid labors and 216,621 unpaid
ones. As Adachi et al.16 reported, it was assumed that
proportion of step 3 and 4 among either paid or un-
paid labors was 39.4% (sum of 20.7% for step 3 and
18.7% for step 4). Furthermore, it was estimated that
the introduction of salmeterol resulted in a reduction
of lost labor that would save about 105.4 billion yen
(782,810 yen × 341,679 persons × 39.4%) in the paid
group and savings of about 64.5 billion yen (756,414
yen × 216,621 persons × 39.4%) in the unpaid group.
These figures were obtained by expanding the pro-
ductivity losses determined in the paid and unpaid
groups involved in our study to the wider population.
It was assumed that all the labors with asthma would
benefit from the introduction of salmeterol．
SENSITIVITY ANALYSIS ON ADJUSTMENT OF
STEP 2
A one-way sensitivity analysis that excluded those
data relating to patients with step 2 asthma was un-
dertaken. Following the analysis, there remained a
statistically significant reduction (p < 0.001) in lost
productivity in paid patients following the introduc-
tion of salmeterol , resulting in savings of approxi-
mately 800,000 yen. Similar results were observed in
unpaid patients ; following the introduction of sal-
meterol, there were approximately 60 fewer days of
lost productivity (p < 0.001 ) . These findings con-
firmed that the original results were not influenced
by the inclusion of patients with step 2 disease．
DISCUSSION
In the present study, the effect of the introduction of
salmeterol on productivity loss induced by asthma
was examined for the first time in Japan. In terms of
the study design, we consider that our study adhered
to validity hierarchy based on clinical medicine study
types categorized by the Agency for Health Care Pol-
icy and Research , 17 such that it was a level III
evidence-based medicine trial. Such level III trials are
defined as well-designed observational studies , and
include comparative and correlation studies and case-
controlled studies. As a consequence of its level III
status, our study does not contain high evidence level
results , and we acknowledge that interpretation of
the results is limited. However, our study does pro-
vide valuable information when the fact that a scarcity
of clinical medical researchers in Japan makes it diffi-
cult to conduct a meta-analysis, large-scale random-
ized controlled trial (RCT) , or cohort observation
study is considered. Moreover, we believe that our
study conforms to the clinical situation and can offer
important information relevant to drug-selection deci-
sions as it is generally said that meta-analyses and
RCTs have high internal reliability but low external
validity,18 and do not reflect the true clinical situation.
The inclusion of patients with step 2 disease may
be seen to have influenced the study results. How-
ever, because patients with step 2 asthma often re-
ceive salmeterol in general practice in order to avoid
asthma exacerbations and prevent disease progres-
sion, patients with step 2 disease were continuously
included in this study. A one-way sensitivity analysis
that excluded such patients showed differences in an-
nual productivity loss in both paid and unpaid labors
that were similar to those seen for the original unad-
justed results．
In the current study, we adopted and analyzed the
productivity loss relevant to patients and employers.
In general, productivity costs include both“morbidity
cost”and“mortality cost”but, in this paper,“morbid-
ity cost”alone was adopted. For estimation of the
productivity loss during periods associated with
asthma, we used the prevalence-based human capital
approach. This method is advantageous in that esti-
mation of the productivity loss is readily performed
and it equates with estimation of short-term produc-
tivity loss. On the other hand, this approach does not
completely accurately reflect the status of each pa-
tient and may overestimate productivity loss in some
cases. For example, supposing a full-time worker is
absent from work due to disease or continues to work
while in a poor condition due to a disease, there may
be no real loss of productivity if the work can be post-
poned or is supplemented by other workers. There is
another method for estimation of productivity loss
known as the Friction-costs Approach,19 which esti-
mates a productivity loss including the period of train-
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Table 3 Clinical findings before and after the introduction of salmeterol 
Unpaid labors (n = 21)Paid labors (n = 33)Clinical outcomes (annual)
50.875.2Before
SFD 210.0195.9After
159.2＊＊＊ (99.4―218.9)120.7＊＊＊ (83.2―158.2)Diference (CI)
235.0248.4Before
SFN 319.3290.9After
 84.3＊＊＊ (24.2―144.4) 42.5＊＊＊ (-17.5―102.3)Diference (CI)
8.78.7Before
Unscheduled visit 4.92.5After
 3.8 NS (-10.9―3.3) 6.2＊＊＊ (2.9―9.5)Diference (CI)
SFD: Symptom-free days, SFN: Symptom-free nights, CI: confidence interval
Paid labors: Patients who have regular or iregular incomes
Unpaid labors: Patients without regular or iregular income
＊＊＊p < 0.001, NS: not significant by Wilcoxon’ ssigned rank test
Table 4 Corelation between productivity loss and 
symptom-free day and night (r)
Symptom-free 
night
Symptom-free 
day
-0.350＊-0.689＊＊＊Paid labors (n = 33)
-0.645＊＊-0.746＊＊＊Unpaid labors (n = 21)
＊＊＊p < 0.001
＊＊p < 0.01
＊p < 0.05
Paid labors: Patients who have regular or iregular incomes
Unpaid labors: Patients without regular or iregular income
ing for a supplementary worker succeeding the pa-
tient in addition to the period of absence of the pa-
tient. Although this method is said to reflect the ac-
tual productivity loss, we considered it unfit for the
estimation of productivity loss for our purposes be-
cause it is not suitable for the estimation of a short-
term productivity loss. In Canada, there has been a
report 20 that estimated the productivity loss in
asthma patients expressed in sickness expenses us-
ing this friction-costs approach．
Although we did not use a friction-costs approach
in this study, we consider that the results obtained
suggest that the introduction of salmeterol for asthma
treatments can significantly reduce productivity loss.
The absolute values obtained in our study provide
decision-makers with tentative indications of the ex-
tent of indirect financial savings that may be possible
in association with salmeterol．
As part of the estimation of the impact of the intro-
duction of salmeterol on society in general, we per-
formed calculations to convert the productivity loss in
the unpaid group to a monetary value . It was as-
sumed that unpaid group would have received the
same daily wages as those in the paid group. Experts
debate the validity of converting the productivity loss
of a person without an income to a monetary value, so
we have presented the financial savings estimations
in the paid and unpaid groups separately without inte-
gration in order to avoid potentially misleading the
decision maker.
One limitation of economic analysis is that the re-
sults vary greatly depending on various conditions
such as those mentioned in the preceding discussion.
We consider that true medical economic evaluation of
a drug involves comprehensive assessment of all di-
rect costs , patient’s health-related quality of life
(HRQoL) or patient’s satisfaction in addition to the in-
direct cost of the productivity loss . Therefore , we
have examined direct costs separately and have previ-
ously reported21 the result at the Annual Meeting of
the Japanese Society of Allergology. Furthermore, a
questionnaire survey in a patient population similar to
that in this study examining patient’s satisfaction with
treatment has revealed that 90% or more patients
were satisfied with the introduction of salmeterol.3
In foreign countries , it has also been reported22
that the combination of ICS and salmeterol showed a
significant improvement in clinical indices , such as
SFDs, in comparison to combination therapy involv-
ing a leukotriene receptor antagonist . Salmeterol-
based therapy was the most cost effective option, as it
reduced the frequency of hospitalization and unex-
pected hospital visits and, thus, reduced direct costs.
We consider that this foreign report supports the re-
sults of our medical economic examination of
salmeterol-based therapy.21
As we were also interested in the indirect effect of
the introduction of salmeterol on a medical institu-
tion, we totaled the number of patients first consult-
ing our hospital for 2 years before and after the intro-
duction of salmeterol and found that the number of
patients increased by approximately 28%. This sug-
gested that the introduction of salmeterol reduced
the number of unscheduled patient visits and, there-
fore, increased the time that was available for exami-
nation of more patients, thereby indirectly benefiting
the medical institution. We plan to present a separate
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report detailing this topic.
DISCUSSION
As discussed above, comprehensive examination of
the significance of the introduction of salmeterol for
the treatment of asthma and its effect on asthma-
related productivity loss is highly important not only
from clinical and economic points of view, but also
from a humanistic viewpoint. The results of this par-
ticular study show that the introduction of salmeterol
to the range of treatments currently available for
asthma in Japan has had a beneficial impact on clini-
cal symptoms and, as a consequence, has reduced
loss of productivity from asthma-related causes. It is
evident that the introduction of salmeterol for asthma
treatment is beneficial for patients , medical institu-
tions and the economy in general．
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